Actionable news
All posts from Actionable news
Actionable news in BLCM: BELLICum PHARMACEUTICALS Inc,

Departure of Directors or Certain

On March 31, 2016, the Board of Directors (the Board) of Bellicum Pharmaceuticals, Inc. (the Company), approved a six month extension of the Employment Agreement, dated April 6, 2015, between the Company and Kevin M. Slawin, M.D., the Chief Technology Officer and a director of the Company (the Employment Agreement), in accordance with the provisions of the Employment Agreement. The Employment Agreement and Dr. Slawins position as an employee of the Company will terminate on December 31, 2016.

The Board also approved the terms of a six month consulting agreement between Dr. Slawin and the Company, effective January 1, 2017 through June 30, 2017 (the Consulting Agreement). Pursuant to the terms of the Consulting Agreement, following termination of the Employment Agreement, Dr. Slawin agreed to serve as a special advisor to the Science Committee of the Board, undertaking special projects as requested by the Science Committee or the Board. The Consulting Agreement provides that Dr. Slawin will be paid a monthly consulting fee of $25,000 during the six-month term of the agreement. In addition, Dr. Slawin will be entitled to receive healthcare benefits during the term of the Consulting Agreement and also will be entitled to reimbursement for documented expenses under the Companys reimbursement policy.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Bellicum Pharmaceuticals, Inc.


/s/ Ken Moseley

Ken Moseley

Senior Vice President and General Counsel

makes a similar move, sign up!